The world of mental health treatment is abuzz with the potential of psychedelics and cannabis, but recent studies have cast a shadow of doubt on their effectiveness. In this article, we'll delve into the findings and explore the implications, offering a critical analysis of these emerging therapies.
The Rise of Psychedelic and Cannabis Prescriptions
Australia has seen a notable increase in prescriptions for psychedelic drugs and cannabis, particularly for mental health disorders like depression. This trend has sparked curiosity and hope among those seeking alternative treatments.
Scant Evidence for Psychedelic Efficacy
Three recent studies have thrown cold water on the enthusiasm. Two studies published in JAMA Psychiatry compared the effectiveness of psychedelics to standard antidepressants, and the results were underwhelming. The first study reviewed trials on LSD, psilocybin, peyote, and ayahuasca, concluding that these substances performed no better than traditional antidepressants for treating depression. The second study, which trialled psilocybin, was inconclusive.
Cannabis: No Evidence for Mental Health Treatment
A separate study published in The Lancet this week found no evidence from 54 clinical trials that cannabis and cannabinoids were effective treatments for depression, anxiety, or PTSD. This lack of evidence raises concerns about the widespread use of these substances for mental health conditions.
Challenges in Studying Cannabinoids and Psychedelics
The gold standard for medical research, double-blind clinical trials, is challenging with these substances. Participants often know what they're taking, which can influence the results. This issue was addressed in the JAMA Psychiatry studies by comparing psychedelics trials with antidepressant trials where participants were aware of their treatment.
The Hype vs. Evidence
Sam Moreton, a lecturer in psychology, notes that the hype around psychedelic therapy has outpaced the evidence. While there are theoretical reasons to believe in their potential, the field has methodological problems. The second JAMA Psychiatry study, for instance, used careful methods to keep patients ignorant of their treatment, but 86% of participants still guessed correctly.
The Need for Further Research
Experts like Dr. Jack Wilson emphasize the importance of more research to understand the effects of these treatments. The TGA's rescheduling of psilocybin and MDMA in 2023 has made it easier for patients to access these drugs as medicines, but caution is advised.
Combining Psychedelics with Psychotherapy
Susan Rossell, a neuropsychologist, suggests that the focus should be on identifying the right conditions and patients for psychedelic therapy. Many clinical trials lack appropriate psychotherapeutic support, which is crucial to help patients process their experiences. Rossell predicts that including thorough psychotherapy alongside psychedelics could produce more positive evidence.
Safety and Caution
While supporting psychedelics as a potential therapy, Rossell emphasizes the need for caution and a step-by-step approach. There are safety issues with any intervention, and tried-and-tested interventions already exist for many mental health conditions. These experimental interventions should be considered only after other treatments have failed.
The Cannabis Prescription Boom
Medicinal cannabis, legal in Australia since 2016, has seen a surge in accessibility. Dr. Wilson's study, which followed a similar process to the JAMA Psychiatry study, found tentative evidence for the treatment of conditions like Tourette's syndrome and insomnia but no evidence for depression, anxiety, or PTSD. Both cannabis and psychedelics can worsen certain mental health conditions, highlighting the need for careful consideration.
Conclusion
The recent studies serve as a reminder that while psychedelics and cannabis show promise, we must proceed with caution. Further research is crucial to understand their effects and ensure their safe and effective use. As we navigate these emerging therapies, a balanced and evidence-based approach is essential.
